Divergent unprotected peptide macrocyclisation by palladium-mediated cysteine arylation

• Main Authors: Reilly, John (Author), Rojas, Anthony Jose (Contributor), Zhang, Chi (Contributor), Vinogradova, Ekaterina V. (Contributor), Buchwald, Nathan (Contributor), Pentelute, Bradley L. (Contributor), Buchwald, Stephen Leffler (Contributor)
• Other Authors: Massachusetts Institute of Technology. Department of Chemistry (Contributor)
• Format: Article
• Language: English
• Published: Royal Society of Chemistry (RSC), 2018-01-10T15:31:37Z.
• Subjects: Article
• Online Access: Get fulltext

Macrocyclic peptides are important therapeutic candidates due to their improved physicochemical properties in comparison to their linear counterparts. Here we detail a method for a divergent macrocyclisation of unprotected peptides by crosslinking two cysteine residues with bis-palladium organometallic reagents. These synthetic intermediates are prepared in a single step from commercially available aryl bis-halides. Two bioactive linear peptides with cysteine residues at i, i + 4 and i, i + 7 positions, respectively, were cyclised to introduce a diverse array of aryl and bi-aryl linkers. These two series of macrocyclic peptides displayed similar linker-dependent lipophilicity, phospholipid affinity, and unique volume of distributions. Additionally, one of the bioactive peptides showed target binding affinity that was predominantly affected by the length of the linker. Collectively, this divergent strategy allowed rapid and convenient access to various aryl linkers, enabling the systematic evaluation of the effect of appending unit on the medicinal properties of macrocyclic peptides.
National Institutes of Health (U.S.) (Grant GM-46059)
National Institutes of Health (U.S.) (Award NIH S10OD01632)
National Science Foundation (U.S.) (Grant CHE-9808061)